The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more potent ...
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...
Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with ...
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
For those with major depression, there is a new treatment option - one that offers hope when patients are not responding to existing treatment. The ...
Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...